{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:08:21Z","timestamp":1784088501055,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","award":["10.13039\/100,009,945"],"award-info":[{"award-number":["10.13039\/100,009,945"]}],"id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106897","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:42:37Z","timestamp":1764808957000},"page":"106897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region"],"prefix":"10.1016","volume":"105","author":[{"given":"Ho Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J.","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sun","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocksy Fransisca V","family":"Situmeang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasitorn","family":"Siritho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Tien Trong","family":"Nghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lau Yuk Lun","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Loke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru Jin","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-5609","authenticated-orcid":false,"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106897_bib0007","unstructured":"Administration USFaD. FDA approves new oral treatment for multiple sclerosis2019 February 2025. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-treatment-multiple-sclerosis."},{"key":"10.1016\/j.msard.2025.106897_bib0049","unstructured":"Agency EM. Mavenclad: EPAR -product information 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf."},{"key":"10.1016\/j.msard.2025.106897_bib0006","unstructured":"Agency. EM. MAVENCLAD: assessment Report2017 March 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mavenclad-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.msard.2025.106897_bib0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.vhri.2021.03.007","article-title":"Economic evaluation of cladribine tablets in patients with high disease activity-relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia","volume":"25","author":"Bohlega","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.msard.2025.106897_bib0017","first-page":"35","article-title":"Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis","volume":"8","author":"Boyko","year":"2018","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"10.1016\/j.msard.2025.106897_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103385","article-title":"Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis","volume":"57","author":"Brochet","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104951","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0048","first-page":"1","article-title":"Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-\u03b1 inhibitors in clinical practice","volume":"12","author":"Chen","year":"2018","journal-title":"Biologics"},{"key":"10.1016\/j.msard.2025.106897_bib0018","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-ANZAN.38","article-title":"039 Rates of lymphopenia in years 1\u20134 in patients with relapsing multiple sclerosis treated annually with cladribine tablets","volume":"89","author":"Cook","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.msard.2025.106897_bib0046","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106123","article-title":"162. Long-term effectiveness of cladribine tablets over 4 years in relapsing multiple sclerosis: results from the MAGNIFY-MS Extension study","volume":"92","author":"De Stefano","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.msard.2025.106897_bib0008","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40263-018-0562-0","article-title":"Cladribine Tablets: a review in relapsing MS","volume":"32","author":"Deeks","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106897_bib0041","series-title":"26th Annual Meeting of the European Charcot Foundation","article-title":"Cladribine: 14 years brain atrophy and clinical follow-up","author":"Dive","year":"2020"},{"issue":"4","key":"10.1016\/j.msard.2025.106897_bib0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s41669-021-00282-7","article-title":"A model-based economic evaluation of Cladribine versus Alemtuzumab, Ocrelizumab and Natalizumab for the treatment of relapsing-remitting multiple sclerosis with high disease activity in Chile","volume":"5","author":"Espinoza","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.msard.2025.106897_bib0036","unstructured":"(eMC) EMC. MAVENCLAD 10 mg tablets2024 February 2025. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/8435\/smpc."},{"issue":"2","key":"10.1016\/j.msard.2025.106897_bib0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician's review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol Ther."},{"issue":"5","key":"10.1016\/j.msard.2025.106897_bib0004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.msard.2025.106897_bib0005","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.msard.2025.106897_bib0020","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.msard.2025.106897_bib0043","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.msard.2025.106897_bib0019","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of Multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.msard.2025.106897_bib0053","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with cladribine tablets beyond year 4: a position statement by Southeast European Multiple Sclerosis Centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.msard.2025.106897_bib0027","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.msard.2025.106897_bib0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.msard.2025.106897_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/1352458520925369","article-title":"Aggressive multiple sclerosis (1): towards a definition of the phenotype","volume":"26","author":"Iacobaeus","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2025.106897_bib0040","series-title":"41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Treatment continuation with cladribine tablets (CladT) beyond year 4\u2013 Second interim analysis of the CLIP-5 study","author":"Korsukewitz","year":"2025"},{"issue":"24","key":"10.1016\/j.msard.2025.106897_bib0003","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.4103\/0366-6999.195475","article-title":"Development of evidence-based recommendations: implications for preparing expert consensus statements","volume":"129","author":"Kwong","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"10.1016\/j.msard.2025.106897_bib0022","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1001\/archneur.63.12.1686","article-title":"Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review","volume":"63","author":"Langer-Gould","year":"2006","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.msard.2025.106897_bib0016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.msard.2025.106897_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42466-019-0005-5","article-title":"Navigating choice in multiple sclerosis management","volume":"1","author":"Linker","year":"2019","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.msard.2025.106897_bib0030","series-title":"Congress of the European Academy of NeurologY","first-page":"491","article-title":"Switch to oral cladribine from first line DMD in MS: 2nd interim analysis of CLAD CROSS","author":"Maniscalco AK","year":"2023"},{"key":"10.1016\/j.msard.2025.106897_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104169","article-title":"Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon","volume":"67","author":"Matni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0044","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fneur.2020.00489","article-title":"Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials","volume":"11","author":"Moccia","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2025.106897_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104403","article-title":"High persistence and low adverse events burden in cladribine treated MS patients from Argentina","volume":"68","author":"Negrotto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0031","series-title":"Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial \u2013 Interim Analysis","author":"Peter Sguigna","year":"2024"},{"issue":"6","key":"10.1016\/j.msard.2025.106897_bib0023","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458516665496","article-title":"Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study","volume":"23","author":"Pitteri","year":"2017","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.msard.2025.106897_bib0001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.msard.2025.106897_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14737167.2019.1635014","article-title":"Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain","volume":"20","author":"Poveda","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"17","key":"10.1016\/j.msard.2025.106897_bib0037","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106897_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0052","series-title":"Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting","article-title":"Efficacy and safety of cladribine tablets in a large, real-world, multicenter United States population","author":"Ravi Dukkipati","year":"2025"},{"key":"10.1016\/j.msard.2025.106897_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105380","article-title":"Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study","volume":"82","author":"Rog","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.msard.2025.106897_bib0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/j.msard.2025.106897_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106897_bib0051","series-title":"41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Real-world experience with Cladribine (Mavenclad) in the MSBase Registry 2025","author":"Spelman","year":"2025"},{"issue":"13","key":"10.1016\/j.msard.2025.106897_bib0024","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458519877810","article-title":"The long-term outcomes of CIS patients in the Barcelona inception cohort: looking back to recognize aggressive MS","volume":"26","author":"Tintore","year":"2020","journal-title":"Mult Scler"},{"issue":"7_supplement_1","key":"10.1016\/j.msard.2025.106897_bib0039","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1212\/WNL.0000000000205065","article-title":"Patients with multiple sclerosis in year 5 after initiation of treatment with cladribine tablets: analysis of longitudinal prescription data from Germany (P8-6.017)","volume":"102","author":"von der Ma\u00dfen","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106897_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.11.069","article-title":"Long term effectiveness of Cladribine in patients enrolled in the CLARITY trial: real world experience from the Lebanese cohort","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:30:40Z","timestamp":1781076640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":53,"alternative-id":["S2211034825006352"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106897","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106897"}}